LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GW843682X | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1557 | 5578 | 0.2792 | -0.3248 |
| SK-BR-3 | HG-5-113-01 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 3242 | 5578 | 0.5812 | 0.2303 |
| SK-BR-3 | HG-5-88-01 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 4381 | 5578 | 0.7853 | 0.6054 |
| SK-BR-3 | Imatinib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 5523 | 5578 | 0.9900 | 0.9817 |
| SK-BR-3 | JNK-9L | 1.11 | uM | LJP6 | 72 | hr | 2543 | 2948 | 5578 | 0.5285 | 0.1334 |
| SK-BR-3 | JW-7-24-1 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 3714 | 5578 | 0.6658 | 0.3857 |
| SK-BR-3 | Lapatinib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 2160 | 5578 | 0.3872 | -0.1263 |
| SK-BR-3 | LDN-193189 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5893 | 5578 | 1.0565 | 1.1038 |
| SK-BR-3 | Linifanib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 5508 | 5578 | 0.9874 | 0.9768 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5013 | 5578 | 0.8987 | 0.8137 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP5 | 72 | hr | 2543 | 1700 | 5578 | 0.3047 | -0.2779 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1366 | 5578 | 0.2449 | -0.3878 |
| SK-BR-3 | MK2206 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 3610 | 5578 | 0.6472 | 0.3516 |
| SK-BR-3 | Neratinib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 1471 | 5578 | 0.2637 | -0.3533 |
| SK-BR-3 | Nilotinib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 6123 | 5578 | 1.0976 | 1.1793 |
| SK-BR-3 | Nintedanib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 4995 | 5578 | 0.8954 | 0.8078 |
| SK-BR-3 | NU7441 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 4652 | 5578 | 0.8340 | 0.6949 |
| SK-BR-3 | Dactolisib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 2073 | 5578 | 0.3716 | -0.1550 |
| SK-BR-3 | NVP-TAE684 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 4800 | 5578 | 0.8605 | 0.7436 |
| SK-BR-3 | Palbociclib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 4116 | 5578 | 0.7379 | 0.5183 |
| SK-BR-3 | PD0325901 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 4778 | 5578 | 0.8565 | 0.7362 |
| SK-BR-3 | PD0325901 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 4749 | 5578 | 0.8514 | 0.7269 |
| SK-BR-3 | PD173074 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 5565 | 5578 | 0.9977 | 0.9957 |
| SK-BR-3 | PD184352 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5706 | 5578 | 1.0228 | 1.0420 |
| SK-BR-3 | Pelitinib | 1.11 | uM | LJP5 | 72 | hr | 2543 | 1697 | 5578 | 0.3043 | -0.2788 |